PTPRD and non-small cell lung carcinoma: Another subgroup analysis conducted based on cancer types showed that PTPRD/PTPRT mutant patients treated with ICIs had significantly longer OS than WT patients in NSCLC and SKCM, which is consistent with the results of previous studies (17, 33).